Skip to main content
Equibles

AWHL · Aspira Women's Health Inc. · Metrics

Track AWHL — free

Use AWHL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AWHL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.21 -0.01 (-4.55%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Given the above conditions, there is substantial doubt about our ability to continue as a going concern within one year after the date these consolidated interim financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$9.80M
Shares
46.63M
Volume · Oct 20 18.86K Avg daily vol (3M) 13.99K

AWHL metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.21
Market cap
$9.80M

Price action

20 metrics
Price change (1W)
-19.2%
Price change (30D)
-22.2%
Price change (3M)
-47.5%
Price change (6M)
-46.2%
Price change (YTD)
-66.7%
Price change (1Y)
-56.3%
Trailing year
Price change (5Y)
—
52-week high
$0.63
52-week low
$0.21
Change from 52-week high
-66.7%
Change from 52-week low
+0.0%
Annualized volatility
140.7%
Annualized volatility (3M)
103.5%
Beta
1.8
RSI (14D)
37.0
Price vs SMA 50
-24.0%
Price vs SMA 200
-44.6%
Avg volume (3M)
13,992
Relative volume
1.4
Average dollar volume
$4,305

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
46.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
47.0×
reciprocal yield 2.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
43.9×
reciprocal yield 2.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-102.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.6×
reciprocal yield 9.4%
EV / revenue historical average (5Y)
10.7×
reciprocal yield 9.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-11-14

Profitability

9 metrics
Gross margin
—
Operating margin
-3,094.6%
Trailing 12 months
Net margin
-4,486.5%
Gross profit (TTM)
$5.02M
Operating profit (TTM)
−$6.90M
Net income (TTM)
−$10.01M
Trailing 12 months
Diluted EPS (TTM)
$-0.31
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-0.93
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.16

Growth

11 metrics
Revenue growth YoY
-89.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$223,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.4%
Year over year · more shares
Revenue CAGR (3Y)
-65.3%
Revenue CAGR (5Y)
-40.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-225.6%
Debt / equity
—
Current ratio
0.5
EBITDA (TTM)
−$6.73M
Free cash flow (TTM)
—
Quick ratio
0.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$683,000
Latest balance sheet
Cash & equivalents
$477,000
Total assets
$4.43M
Total debt
$1.16M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.56M
Capital expenditures (TTM)
$37,000
R&D (TTM)
$3.12M
SG&A (TTM)
—
Stock compensation (TTM)
$473,000
R&D / revenue
1,398.7%
Stock compensation / revenue
212.1%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
23 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 926617 Visit website Investor relations